Polynovo Stock

Polynovo Net Margin

The Net Profit Margin of Polynovo (PNV.AX) as of Aug 6, 2026 is 10.35 %. In the previous year, Net Profit Margin was 5.02 % — a change of 105.94% (higher).

Net Margin

10.35 %

YoY

105.94%

Last updated:

Net Profit Margin of Polynovo is 2026 10.35 % . Net Profit Margin of Polynovo was 2025 5.02 % . It decreases by 105.94% higher compared to the previous year.

Polynovo's net margin stands at 10.3%, up from -15.8% several years earlier.

Access this data via the Eulerpool API

Polynovo Stock analysis

What does Polynovo do? Polynovo Ltd is an Australian BioTech company that specializes in the development and manufacturing of medical implants. The company was founded in 1986 under the name Regeneus Ltd and is headquartered in Melbourne. Polynovo's history began with the development of products for the veterinary field. In 2000, the company received approval for the sale of its first human products, which were used for wound treatment. In 2014, the company was renamed Polynovo to emphasize its focus on biological implants for human tissue. Polynovo utilizes a revolutionary technology called NovoSorb, which allows for the production of biodegradable polymer films in various shapes and sizes. These are then used as implants in the human body and naturally degrade within a predetermined timeframe. Polynovo is divided into various divisions, including wound care, plastic surgery, and orthopedics. In wound care, the company offers products that aim to prevent infections and promote natural healing processes. The plastic surgery division provides implants for breast reconstruction and fat transplantation. In orthopedics, Polynovo manufactures implants for joints, bones, and tendons. An example of a Polynovo product is NovoSorb BTM (Biodegradable Temporary Matrix), which is used in burns and other skin defects. The matrix stimulates healing and the formation of new tissue, restoring a normal appearance to the patient. Polynovo's business model is based on long-term relationships with hospitals, medical professionals, and government agencies. The company heavily invests in research and development to continuously improve and expand its technology and product range. Through partnerships with other companies and academic institutions, Polynovo is working towards global distribution of its products. Overall, Polynovo has received various awards over the years, including an innovation award from the Australian Trade Commission, and has been recognized multiple times as one of Australia's fastest-growing companies. In conclusion, Polynovo is an innovative and successful company specializing in the development and manufacturing of biological implants. Thanks to its NovoSorb technology, the company can offer products that help accelerate the healing process and facilitate faster patient recovery. Polynovo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polynovo stock

Net Profit Margin of Polynovo is 10.35 % in 2026.

Net Profit Margin of Polynovo changed from 5.02 % to 10.35 %, representing a 105.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Polynovo since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Polynovo with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Polynovo

All Key Metrics — Polynovo